For instance, Barragan [27] and Tian [28] indicated that NQO1 polymorphism rs1800566 has predictive usefulness toward clinical response to induction therapy (anthracycline- and cytarabine-based regimen) in acute myeloid leukemia (AML) and platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients, respectively. Here, NQO1 is linked to non-small cell lung carcinoma.